Different strategies for cancer treatment: mathematical modelling (Q634423): Difference between revisions
From MaRDI portal
Created a new Item |
Changed an Item |
||
(5 intermediate revisions by 4 users not shown) | |||
Property / author | |||
Property / author: Vladimir Al. Osipov / rank | |||
Property / author | |||
Property / author: Vladimir Al. Osipov / rank | |||
Normal rank | |||
Property / MaRDI profile type | |||
Property / MaRDI profile type: MaRDI publication profile / rank | |||
Normal rank | |||
Property / OpenAlex ID | |||
Property / OpenAlex ID: W2120669479 / rank | |||
Normal rank | |||
Property / arXiv ID | |||
Property / arXiv ID: q-bio/0605046 / rank | |||
Normal rank | |||
links / mardi / name | links / mardi / name | ||
Latest revision as of 15:43, 18 April 2024
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Different strategies for cancer treatment: mathematical modelling |
scientific article |
Statements
Different strategies for cancer treatment: mathematical modelling (English)
0 references
2 August 2011
0 references
Summary: We formulate and analyse a mathematical model describing immune response to avascular tumour under the influence of immunotherapy and chemotherapy and their combinations as well as vaccine treatments. The effect of vaccine therapy is considered as a parametric perturbation of the model. In the case of a weak immune response, neither immunotherapy nor chemotherapy is found to cause tumour regression to a small size, which would be below the clinically detectable threshold. Numerical simulations show that the efficiency of vaccine therapy depends on both the tumour size and the condition of immune system as well as on the response of the organism to vaccination. In particular, we found that vaccine therapy becomes more effective when used without time delay from a prescribed date of vaccination after surgery and is ineffective without preliminary treatment. For a strong immune response, our model predicts the tumour remission under vaccine therapy. Our study of successive chemo/immuno, immuno/chemo and concurrent chemoimmunotherapy shows that the chemo/immuno sequence is more effective while concurrent chemoimmunotherapy is more sparing.
0 references
immune response
0 references
avascular tumour
0 references
immunotherapy
0 references
chemotherapy
0 references
vaccine therapy
0 references